VA
TRIL

VR Adviser’s Trillium Therapeutics Inc. TRIL Stock Holding History

VR Adviser’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,001,686
Closed -$19.4M – 35
2021
Q2 		$19.4M Sell
2,001,686
-2,038,314
-50% -$19.2M 2.36% 15
2021
Q1 		$43.4M Hold
4,040,000
– – 4.71% 8
2020
Q4 		$59.4M Sell
4,040,000
-3,164,577
-44% -$45.6M 8.74% 3
2020
Q3 		$102M Buy
7,204,577
+414,577
+6% +$4.13M 20.03% 1
2020
Q2 		$54.9M Hold
6,790,000
– – 13.15% 2
2020
Q1 		$27.4M Buy
+6,790,000
New +$25.7M 7.43% 4

Other funds holding TRIL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

VR Adviser's TRIL Position: Q3 2021 in Review

VR Adviser sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 2,001,686 shares — an estimated $19.4M sold.

VR Adviser first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $102M in Q3 2020. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • VR Adviser reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • VR Adviser sold 2,001,686 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $19.4M.
  • VR Adviser first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
  • VR Adviser's Trillium Therapeutics Inc. position peaked at $102M in Q3 2020.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.